Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Autoimmune Disorders

  Free Subscription


1 Am J Kidney Dis
2 Ann Neurol
2 BMC Neurol
1 Brain
1 Curr Opin Immunol
2 Intern Med
1 J Autoimmun
1 J Nephrol
3 J Neuroimmunol
5 J Neurol
1 J Pediatr
2 Lancet
3 Mult Scler
1 N Engl J Med
1 Nat Rev Neurol
1 Neurologia (Engl Ed)
2 Neurology
1 PLoS Med
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Kidney Dis

  1. ZONOZI R, Laliberte K, Huizenga NR, Rosenthal JK, et al
    Combination of Rituximab, Low-dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Am J Kidney Dis. 2021 Jun 23. pii: S0272-6386(21)00690.
    PubMed         Abstract available

    Ann Neurol

    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.

  3. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    PubMed         Abstract available

    BMC Neurol

  4. EHTESHAM N, Rafie MZ, Mosallaei M
    The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.
    BMC Neurol. 2021;21:246.
    PubMed         Abstract available

  5. AMINI P, Almasi-Hashiani A, Sahraian MA, Najafi M, et al
    Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series.
    BMC Neurol. 2021;21:235.
    PubMed         Abstract available


  6. BITTNER S, Oh J, Havrdova EK, Tintore M, et al
    The potential of serum neurofilament as biomarker for multiple sclerosis.
    Brain. 2021 Jun 28. pii: 6310737. doi: 10.1093.
    PubMed         Abstract available

    Curr Opin Immunol

  7. SHIH HP, Ding JY, Yeh CF, Chi CY, et al
    Anti-interferon-gamma autoantibody-associated immunodeficiency.
    Curr Opin Immunol. 2021;72:206-214.
    PubMed         Abstract available

    Intern Med

  8. TANAKA Y, Takikawa T, Kume K, Kikuta K, et al
    IgG4-related Diaphragmatic Inflammatory Pseudotumor.
    Intern Med. 2021;60:2067-2074.
    PubMed         Abstract available

  9. SAKATA K, Kikuchi J, Emoto K, Kotaki T, et al
    Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review.
    Intern Med. 2021;60:2135-2143.
    PubMed         Abstract available

    J Autoimmun

  10. LINGEL H, Meltendorf S, Billing U, Thurm C, et al
    Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals.
    J Autoimmun. 2021;122:102682.
    PubMed         Abstract available

    J Nephrol

  11. GEETHA D, Attarwala N, Zhang C, Kant S, et al
    Serum and urinary metabolites discriminate disease activity in ANCA associated glomerulonephritis in a pilot study.
    J Nephrol. 2021 Jun 28. pii: 10.1007/s40620-021-01095.
    PubMed         Abstract available

    J Neuroimmunol

  12. UZAWA A, Akamine H, Kojima Y, Ozawa Y, et al
    High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis.
    J Neuroimmunol. 2021;358:577634.
    PubMed         Abstract available

  13. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed         Abstract available

  14. MOSTAFA GA, Meguid NA, Shehab AAS, Elsaeid A, et al
    Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity.
    J Neuroimmunol. 2021;358:577638.
    PubMed         Abstract available

    J Neurol

  15. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.

  16. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    PubMed         Abstract available

  17. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.

  18. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed         Abstract available

  19. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed         Abstract available

    J Pediatr

    50 Years Ago in TheJournal ofPediatrics: When "Chronic Active Hepatitis" Became Autoimmune Hepatitis.
    J Pediatr. 2021;234:204.


  21. TSAGKAS C, Schafer S, Baumgartner A, Muller J, et al
    Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.
    Lancet. 2021;397:2194.

  22. MCGINLEY MP, Cohen JA
    Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    Lancet. 2021 Jun 24. pii: S0140-6736(21)00244.
    PubMed         Abstract available

    Mult Scler

  23. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed         Abstract available

  24. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed         Abstract available

  25. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed         Abstract available

    N Engl J Med

  26. WERTH VP, Joly P, Mimouni D, Maverakis E, et al
    Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
    N Engl J Med. 2021;384:2295-2305.
    PubMed         Abstract available

    Nat Rev Neurol

  27. WOOD H
    TSPO levels in multiple sclerosis lesions reflect microglial density rather than activation state.
    Nat Rev Neurol. 2021 Jun 29. pii: 10.1038/s41582-021-00533.

    Neurologia (Engl Ed)

  28. JIMENEZ-ALONSO J, Navarrete-Navarrete N, Jimenez-Jaimez E, Jaimez L, et al
    Myasthenia gravis and systemic lupus erythematosus: presentation of 5 cases and PubMed review.
    Neurologia (Engl Ed). 2021 Jun 23. pii: S2173-5808(21)00084.


  29. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    PubMed         Abstract available

  30. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    PubMed         Abstract available

    PLoS Med

  31. MANOUSAKI D, Harroud A, Mitchell RE, Ross S, et al
    Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study.
    PLoS Med. 2021;18:e1003536.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  32. COLOMBO E, Triolo D, Bassani C, Bedogni F, et al
    Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.